Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ilya Yakavets has a total of 270 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open-source hardware for biomanufacturing

    by Caner Dikyol, Daniel Hocevar, Milica Radisic, Yimu Zhao, Ilya Yakavets

  • Cyclodextrin-based photoactive liposomal nanoparticles for tumor targeting

    by Ilya Yakavets

    Ciblage tumoral par des nanoparticules photoactivable basée sur des complexes de cyclodextrines encapsulées dans des liposomes: La thérapie photodynamique (PDT) est un traitement alternatif du cancer plus ciblé et moins invasif que les modalités traditionnelles. La Temoporfine (mTHPC, nom sous forme médicamenteuse : Foscan®), est l'un des PS les plus puissants cliniquement approuvés. Cependant, sa faible solubilité en milieu aqueux a provoqué plusieurs complications lors de son administration. La présente étude vise à mettre au point des nanoparticules constituées d’une molécule anticancéreuse couplée à la cyclodextrine intégré dans un liposome (drug-in-cyclodextrin-in-liposome, DCL) en couplant deux systèmes d'administration indépendants : les complexes d'inclusion cyclodextrine-mTHPC et les vésicules liposomales pour améliorer le transport et la pénétration de la mTHPC dans le tissu cible. La formation de complexes d'inclusion entre les cyclodextrines et la mTHPC a été étudiée en détail. Sur la base de ces données, des mTHPC-DCL à simple et double charge ont été préparées, optimisées et caractérisées. Il a été démontré que les mTHPC-DCL sont stables et que presque tous les mTHPC-DCL sont liés à β-CDs dans la lumière aqueuse interne des liposomes. L'influence des DCLs sur l'accumulation, la distribution et l'efficacité photodynamique de la mTHPC a été étudiée dans des modèles cellulaire en monocouche et sphéroïde multicellulaires 3D d’adénocarcinome de pharynx humain (HT29). En utilisant des sphéroïdes, nous avons démontré que le DCL à base de triméthyl-β-CD fournissait une accumulation homogène de la mTHPC dans tout le volume des sphéroïdes tumoraux, suggérant ainsi une distribution optimale de la mTHPC.

  • Open Access

    From conventional screening to self-driving discovery: Organ-on-Chip platforms as engines for AI-guided nanomedicine

    by Kimia Asadi Jozani, Karen Shen, Nicky Anvari, Daniel Hocevar, Rosanna Jiang, Boyang Zhang, Ilya Yakavets, Yimu Zhao


  • Open Access

    Commit: Digital pipette: open hardware for liquid transfer in self-driving laboratories

    by Naruki Yoshikawa, Kevin Angers, Kourosh Darvish, Sargol Okhovatian, Dawn Bannerman, Ilya Yakavets, Milica Radisic, Alán Aspuru-Guzik

    We present an updated version of the digital pipette, an economical 3D-printed device for accurate liquid transfers by robotic arms. The new version supports disposable tip replacement to reduce contamination while maintaining high accuracy.


  • Open Access

    Machine learning-assisted exploration of multidrug-drug administration regimens for organoid arrays

    by Ilya Yakavets, Sina Kheiri, Jennifer Cruickshank, Riley J. Hickman, Faeze Rakhshani, Matteo Aldeghi, Ella M. Rajaonson, Edmond W.K. Young, Alán Aspuru-Guzik, David W. Cescon, et al.

    Combination therapies enhance the therapeutic effect of cancer treatment; however, identifying effective interdependent doses, durations, and sequences of multidrug administration regimens is a time- and labor-intensive task. Here, we integrated machine learning, automation, and large microfluidic arrays of cancer spheroids or patient-derived organoids formed in a tissue-mimetic hydrogel to achieve notable acceleration of the discovery of effective multidrug administration regimens. For the clinically approved drug combination, we found a sequential administration regimen leading to a substantial reduction in the total drug dose, in comparison with concurrent drug supply, both at comparable drug efficacy. For the drugs that are currently under clinical development, we found a synergistic effect of concurrently administered drugs and showed that the synergy diminishes for the sequential drug supply. The developed strategy holds promise for the discovery of effective combination therapies for advanced cancer treatment, including personalized chemotherapies.


  • Spheroid-based skin-on-a-chip platform for the evaluation of the toxicity of small molecules and nanoparticles

    by Dianoosh Kalhori, Faeze Rakhshani, Yingshan Ma, Ilya Yakavets, Sina Kheiri, Ophelie Zeyons, Susanne N. Kolle, Ted Deisenroth, Liangliang Qu, Zhengkun Chen, et al.

    Exposure of human skin to chemical agents may lead to skin sensitization, irritation, and corrosion. Time-efficient toxicity screening is currently achieved using in vitro skin-on-a-chip models; however, these either lack a multilayer structure characteristic of the skin, or require long fabrication time. Here, we report the development and proof-of-concept application of the microfluidic spheroid-based skin-on-a-chip platform utilizing gravity-driven flow and large arrays of multilayer skin spheroids (MSSs). The MSSs containing human dermal fibroblasts in the core and keratinocytes in the shell replicated the dermal and epidermal layers of skin, respectively. Within 3 days, the toxicity of five distinct small molecules was characterized by measuring their IC50 values, which enabled the differentiation of non-irritant chemical agents from the irritant ones and correlated with their in vivo scores for skin irritation. Toxicity screening was extended to nanoparticles, including carbon dots, liposomes, and insecticide-loaded liposomes. This MSS-based skin-on-a-chip microfluidic platform for the safety evaluation of small molecules and nanoparticles has diverse applications in the skincare, pharmaceutical, and agriculture fields.


  • Open Access

    Bayesian Optimization Hackathon for Chemistry and Materials

    by Sterling Baird, Mehrad Ansari, Zartashia Afzal, Qianxiang Ai, Alexander Al-Feghali, Mathieu Alain, Matias Altamirano, Thomas Andrews, Andy Sode Anker, Rija Ansari, et al.

    The Acceleration Consortium and Merck KGaA hosted a 2-day virtual hackathon on March 27- 28, 2024, bringing together scientists to explore, collaborate, and innovate in the field of Bayesian optimization for the physical sciences. Participants were encouraged to select or develop Bayesian optimization algorithms, apply them to benchmarking tasks, design new benchmarks, create instructional tutorials, and describe real-world applications. With over 100 participants across 69 academic, industry, and government organizations located in 59 cities, 19 countries, and 4 continents, this was a global event. The outputs from this event, including developed algorithms, benchmarks, and tutorials, will serve as valuable resources for the research community, in addition to the new skills learned and connections formed. Released projects and general information are available at https://ac-bo-hackathon.github.io/ and other locations linked from individual project pages. This event demonstrates the potential of community-driven research efforts to accelerate advances in Bayesian optimization in chemistry and materials science.


  • Efficient Delivering of a Photodynamic Therapy Drug into Cellular Membranes Rationalized by Molecular Dynamics

    by Basak Koca Fındık, Ilya Yakavets, Henri-Pierre Lassalle, Saron Catak, Antonio Monari

    Photodynamic therapy (PDT) represents a most attractive therapeutic strategy to reduce side-effects of chemotherapy and improve the global quality of life of patients. Yet, many PDT drugs suffer from poor bioavailability and cellular intake, and thus, drug-delivering strategies are mandatory. In this article, we rationalize the behavior of a temoporfin-based PDT drug, commercialized under the name of Foscan, complexed by two β-cyclodextrin units, acting as drug carriers, in the presence of a lipid bilayer. Our all-atom simulations have unequivocally shown the internalization of the drug-delivering complex and suggest its possible spontaneous dissociation in the lipid bilayer core. The factors favoring penetration and dissociation have also been analyzed, together with membrane perturbation due to the interaction with the drug carrier complex. Our results confirm the suitability of this encapsulation strategy for PDT and rationalize the experimental results concerning its efficacy.


  • Open Access

    Microfluidic Platform for Generating and Releasing Patient‐Derived Cancer Organoids with Diverse Shapes: Insight into Shape‐Dependent Tumor Growth

    by Sina Kheiri, Ilya Yakavets, Jennifer Cruickshank, Fatemeh Ahmadi, Hal K Berman, David W. Cescon, Edmond W.K. Young, Eugenia Kumacheva

    Multicellular spheroids and patient‐derived organoids find many applications in fundamental research, drug discovery, and regenerative medicine. Advances in the understanding and recapitulation of organ functionality and disease development require the generation of complex organoid models, including organoids with diverse morphologies. Microfluidics‐based cell culture platforms enable time‐efficient confined organoid generation. However, the ability to form organoids with different shapes with a subsequent transfer from microfluidic devices to unconstrained environments for studies of morphology‐dependent organoid growth is yet to be demonstrated. Here, a microfluidic platform is introduced that enables high‐fidelity formation and addressable release of breast cancer organoids with diverse shapes. Using this platform, the impact of organoid morphology on their growth in unconstrained biomimetic hydrogel is explored. It is shown that proliferative cancer cells tend to localize in high positive curvature organoid regions, causing their faster growth, while the overall growth pattern of organoids with diverse shapes tends to reduce interfacial tension at the organoid‐hydrogel interface. In addition to the formation of organoids with diverse morphologies, this platform can be integrated into multi‐tissue micro‐physiological systems.


  • A Microfluidic Platform for Evaluating the Internalization of Liposome Drug Carriers in Tumor Spheroids

    by Ilya Yakavets, Monica Ayachit, Sina Kheiri, Zhengkun Chen, Faeze Rakhshani, Samantha McWhirter, Edmond W. K. Young, Gilbert C. Walker, Eugenia Kumacheva

    The development of in vitro models recapitulating nanoparticle transport under physiological flow conditions is of great importance for predicting the efficacy of nanoparticle drug carriers. Liposomes are extensively used for drug delivery owing to their biocompatibility and biodegradability and the ability to carry both hydrophilic and hydrophobic compounds. Here, we used a library of liposomes with various dimensions and a microfluidic platform comprising a large array of uniformly sized breast cancer spheroids to explore size-dependent liposome internalization and retention in the spheroids under close-to-physiological interstitial conditions. Such a platform showed promising applications in the preclinical screening of small molecule drugs; however, the capability to deliver nanoparticles in the spheroid interior under close-to-physiological flow conditions was not explored. For the liposomes with diameters in the range of 45-200 nm, we show experimentally and by simulations that in comparison with liposome delivery solely by diffusion, flow significantly enhances liposome internalization in the microgels and mitigates the size-dependent spheroid penetration by the liposomes. The utility of the microfluidic platform was validated by evaluating the efficacy of clinically approved doxorubicin-loaded liposomes (Doxil), which exhibited superior retention in the spheroids under flow conditions, in comparison with free doxorubicin. This MF platform can serve as an in vitro model for screening the efficacy of drugs encapsulated in liposomes and find applications for screening other types of nanoparticle carriers for vaccine delivery, diagnostics, and skincare.